Diagnosis of ascites in infants and children by history, examination and investigations

Ascites

Diagnosis of Ascites in Infants and Children

Diagnosis of ascites in infants and children fromega age of 1month to 18 year

Asmaa abo bakr Ahmed

Doctor

Assiut University

18F-FDG PET combined with CT with iodinated contrast injection

18F-FDG PET combined with CT without injection

Squamous Cell Carcinoma of the Head and Neck

Service Médecine Nucléaire

Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection

Final classification review (Benin, malignant or suspicious)

University Hospital, Caen

Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.

Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
Bevacizumab 25 mg in 1 ml subcutaneously daily: Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.

Bevacizumab

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

To describe MRI response regarding edema and enhancement of glioblastoma and radiation-related brain enhancement when treated with subcutaneous bevacizumab daily. The therapeutic benefit of bevacizumab as regards glioblastoma multiforme (GBM) is largely due to the normalization of brain vasculature. This normalization appears on contrast-enhanced MRI as a reduction in enhancement and reduction in edema. For purposes of this study, any reduction in enhancement/edema by 25% or more will be considered a response.

Number of Participants With Change in Peritumoral Enhancement/Edema

Subcutaneous bevacizumab may have toxicities unique to the subcutaneous administration and not seen with intravenous bevacizumab. During the first 3 weeks we will watch for such toxicities. Toxicities will be described and graded using the Common Toxicity Criteria for Adverse Effects (CTCAE) v3.

Number of Toxicities Reported in Study Participants

Participants may switch from subcutaneous bevacizumab on study to standard of care intravenous bevacizumab. In these participants, we will measure decrease of edema after this switch. A further decrease in edema after making this switch would suggest intravenous to be superior to subcutaneous as regards decreasing edema. The therapeutic benefit of bevacizumab as regards GBM is largely due to the normalization of brain vasculature. This normalization appears on contrast-enhanced MRI as a reduction in edema. For purposes of this study, any reduction in edema by 25% or more will be considered a response.

Number of Participants With Change in Edema After Conversion From Study Treatment to Intravenous Bevacizumab

Overall Study

William L. Read, MD, Principal Investigator

Glioblastoma

Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.

Bevacizumab 25 mg in 1 ml subcutaneously daily

Emory University Hospital Midtown

Emory University Winship Cancer Institutute

A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

William Read

Principal Investigator

Emory University

Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.

Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
D-Galactose: Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.

Galactose

FSPF is reported in relation to its induction of glomerular albumin permeability (Palb) of isolated glomeruli on a range from 0 to 1, with 0 indicative of normal glomeruli and 1 indicative of injury to the permeability barrier. Results will be considered clinically significant if the following criteria is met in response to oral galactose therapy at week 16: Reduction in FSPF to <0.5 Palb or decrease in FSPF by > 0.3 Palb.

Focal Segmental Glomerulosclerosis Permeability Factor (FSPF)

Results will be considered clinically significant if the following criteria is met in response to oral galactose therapy at week 16. Complete remission is defined as (Urine Protein:Creatinine ratio [UPC] <0.2 g/g). Partial remission is defined as UPC 0.2-2 g/g.

Number of Participants Achieving Complete or Partial Remission at 16 Weeks

Asha Moudgil MD, Professor of Pediatrics

Focal Segmental Glomerulosclerosis

Steroid Resistant Nephrotic Syndrome

Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.

D-Galactose

Children's National Medical Center

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study

ovarian neoplasms/edema

Diagnosis of Ascites in Infants and Children

Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection

A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

科學支持的最完整的草藥數據庫